🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

57 results for “Nanjing” Clear

  1. Gum chewing

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Recovery of Bowel Function, Due to Gum Chewing

    phase 3 other active

    1 trial

  2. Lidocaine spray

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Uterine Bleeding

    phase 3 small molecule completed

    1 trial

  3. Lidocaine spray

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Uterine Cervical Dysplasia

    phase 3 other completed

    1 trial

  4. Mevac-A vaccine

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    HAV

    phase 3 mab completed

    1 trial

  5. Camrelizumab Plus Apatinib

    Nanjing Zenshine Pharmaceuticals

    Unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  6. LCAR-B38M CAR-T Cell

    Nanjing Legend Biotech Co.

    Multiple Myeloma

    phase 2 mab terminated

    1 trial

  7. LCAR-B38M CAR-T cell injection

    Nanjing Legend Biotech Co.

    Refractory or Relapsed Multiple Myeloma

    phase 2 mab active

    1 trial

  8. Pre-operative chemotherapy

    Nanjing Zenshine Pharmaceuticals

    Gastric Cancers

    phase 2 small molecule active

    1 trial

  9. Prednisone

    Nanjing Children's Hospital

    Henoch-Schoenlein Purpura Nephritis

    phase 2 small molecule active

    1 trial

  10. Rezvilutamide

    Nanjing Zenshine Pharmaceuticals

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  11. low-dose lymphocyte immunotherapy

    Nanjing Zenshine Pharmaceuticals

    Unexplained Recurrent Miscarriage and Recurrent Implantation Failure

    phase 2 other completed

    1 trial

  12. CAR-T Re-treatment

    Nanjing Legend Biotech Co.

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  13. CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory B-cell Malignancies

    phase 1 mab active

    1 trial

  14. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Lymphoma, B-Cell

    phase 1 small molecule terminated

    1 trial

  15. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Refractory B Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial

  16. Efficacy of LCAR-T2C CAR-T cells

    Nanjing Legend Biotech Co.

    CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

    phase 1 small molecule terminated

    1 trial

  17. Efficacy of LCAR-T2C CAR-T cells

    Nanjing Legend Biotech Co.

    T Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  18. LB1901

    Nanjing Legend Biotech Co.

    T-Cell Lymphoma

    phase 1 mab active

    1 trial

  19. LB1908

    Nanjing Legend Biotech Co.

    Gastric Cancer

    phase 1 mab active

    1 trial

  20. LB2102

    Nanjing Legend Biotech Co.

    Small Cell Lung Cancer Extensive Stage

    phase 1 mab active

    1 trial

  21. LCAR-AIO T cells

    Nanjing Legend Biotech Co.

    Multiple Sclerosis (MS)

    phase 1 mab active

    1 trial

  22. LCAR-AIO T cells

    Nanjing Legend Biotech Co.

    Systemic Lupus Erythematosus (SLE)

    phase 1 mab active

    1 trial

  23. LCAR-AIO T cells

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Autoimmune Diseases

    phase 1 mab terminated

    1 trial

  24. LCAR-AIO cells product

    Nanjing Legend Biotech Co.

    B-cell Lymphoma Recurrent

    phase 1 mab terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources